Artigos com autorizações de acesso público - janis taubeSaiba mais
Não disponíveis em nenhum local: 2
Basal cell carcinomas of the vulva: high-risk human papillomavirus DNA detection, p16 and BerEP4 expression
H Elwood, J Kim, A Yemelyanova, BM Ronnett, JM Taube
The American Journal of Surgical Pathology 38 (4), 542-547, 2014
Autorizações: US National Institutes of Health
Different Biomarker Modalities and Response to Anti–PD-1/PD-L1 Therapies—Reply
S Lu, H Wang, JM Taube
JAMA oncology 6 (2), 299-299, 2020
Autorizações: US National Institutes of Health, Arnold Ventures LLC
Disponíveis em algum local: 138
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
Autorizações: US National Institutes of Health
PD-1 blockade in tumors with mismatch-repair deficiency
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
Autorizações: US National Institutes of Health
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
Autorizações: US National Institutes of Health, Howard Hughes Medical Institute
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167-3175, 2010
Autorizações: US National Institutes of Health
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020-1030, 2014
Autorizações: US National Institutes of Health
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
SL Topalian, JM Taube, RA Anders, DM Pardoll
Nature Reviews Cancer 16 (5), 275-287, 2016
Autorizações: US National Institutes of Health
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy
JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ...
Clinical cancer research 20 (19), 5064-5074, 2014
Autorizações: US National Institutes of Health
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ...
Science translational medicine 4 (127), 127ra37-127ra37, 2012
Autorizações: US National Institutes of Health
Fulminant myocarditis with combination immune checkpoint blockade
DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ...
New England Journal of Medicine 375 (18), 1749-1755, 2016
Autorizações: US National Institutes of Health, Howard Hughes Medical Institute
Neoadjuvant PD-1 blockade in resectable lung cancer
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
Autorizações: US National Institutes of Health, LUNGevity Foundation, USA
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ...
New England Journal of Medicine 386 (21), 1973-1985, 2022
Autorizações: US National Institutes of Health
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
NJ Llosa, M Cruise, A Tam, EC Wicks, EM Hechenbleikner, JM Taube, ...
Cancer discovery 5 (1), 43-51, 2015
Autorizações: US National Institutes of Health
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ...
New England Journal of Medicine 374 (26), 2542-2552, 2016
Autorizações: US National Institutes of Health
Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
S Lyford-Pike, S Peng, GD Young, JM Taube, WH Westra, B Akpeng, ...
Cancer research 73 (6), 1733-1741, 2013
Autorizações: US National Institutes of Health
Neoadjuvant checkpoint blockade for cancer immunotherapy
SL Topalian, JM Taube, DM Pardoll
Science 367 (6477), eaax0182, 2020
Autorizações: US National Institutes of Health
A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer
DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ...
JAMA oncology 3 (8), 1051-1058, 2017
Autorizações: US National Institutes of Health
Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non–small cell lung cancer
KJ Lastwika, W Wilson III, QK Li, J Norris, H Xu, SR Ghazarian, ...
Cancer research 76 (2), 227-238, 2016
Autorizações: US National Institutes of Health
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
Autorizações: US National Institutes of Health
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.